drug pricing

Research in Review

Insulin Pump Therapy Inferior to Insulin Injections in Cost-Effectiveness

06/23/2017

JCP Editors

Continuous subcutaneous insulin infusion (CSII) is associated with increased hypoglycemia encounters and health care expenditures, according to research published in the American Journal of Managed Care (June 21,...

...

06/23/2017

Journal of Clinical Pathways

Department

Pazopanib More Cost-Effective Than Sunitinib for Patients With Renal Cell Carcinoma

04/12/2017

JCP Editors

Medicare patients with advanced renal cell carcinoma benefit from lower costs and hospital admissions if treated with pazopanib (Votrient, Novartis) rather than sunitinib (Sutent, Pfizer). Advanced renal cell...

...

04/12/2017

Journal of Clinical Pathways

Research in Review

Pazopanib Cost-Effective for Patients With Renal Cell Carcinoma

03/28/2017

JCP Editors

Medicare patients with advanced renal cell carcinoma benefit from lower costs and hospital admissions if treated with pazopanib rather than sunitinib, according to research presented at the AMCP Managed Care &...

...

03/28/2017

Journal of Clinical Pathways

Research in Review

Lower Dosage of Prostate Cancer Drug Equally Effective When Taken With Low-Fat Meal

02/17/2017

JCP Editors

Taking one-fourth the recommended dose of a standard drug with a low-fat meal is as effective as taking the recommended dose on an empty stomach for patients with castration-resistant prostate cancer, according to...

Taking...

02/17/2017

Journal of Clinical Pathways

Research in Review

Hormone Receptor-Negative Breast Cancers Gain Greatest Economic Benefit from Trastuzumab

12/13/2016

JCP Editors

The cost-effectiveness of adjuvant trastuzumab (Herceptin, Genentech) may vary based on patient age and disease subtype among women with HER2-positive breast cancer, according to study results published in PLoS...

The...

12/13/2016

Journal of Clinical Pathways

Research in Review

Trastuzumab Biosimilar Approval Could Improve Access to Treatment For Breast Cancer

12/05/2016

JCP Editors

The potential FDA approval of a new biosimilar to trastuzumab may help increase access to the treatment, which is recommended as first-line therapy for patients with ERBB2 (HER2)-positive breast...

The...

12/05/2016

Journal of Clinical Pathways

Perspectives

Frameworks for Assessing the Value of Cancer Drugs: Purely an Academic Exercise?

08/02/2016

Joshua P. Cohen , PhD;

Abstract: As the cost of prescription drugs increases, payers and providers alike have attempted to determine the value of treatments for high-cost disease, including cancer. In this article, the authors discuss the...

...

08/02/2016

Journal of Clinical Pathways

Perspectives

Impact of Government Cost Controls on Treatment Selection for Clinical Pathways

03/08/2016

Scott Guerin , PhD;

Richard G. Stefanacci , DO, MGH, MBA, AGSF, CMD;

Abstract: The increasing emphasis on value-based care has led to the rise of clinical pathways and their use in various health care settings for a number of different disease states. To improve these pathways and...

...

03/08/2016

Journal of Clinical Pathways

Partner Resource

Hillary Clinton`s Plan to Address Drug Costs: Experts Weigh In

10/25/2015

JCP Editors

Since Hillary Clinton announced her proposal to restructure American health care and take on the high costs of treatment, her plans have been met with no shortage of praise and criticism by experts within the health...

Since...

10/25/2015

Journal of Clinical Pathways